These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
771 related items for PubMed ID: 9171934
1. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF. Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW, Chang AE. Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934 [Abstract] [Full Text] [Related]
2. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice. Sumimoto H, Tani K, Nakazaki Y, Tanabe T, Hibino H, Wu MS, Izawa K, Hamada H, Asano S. Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964 [Abstract] [Full Text] [Related]
3. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE. Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710 [Abstract] [Full Text] [Related]
4. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1. Tseng SH, Chen Y, Chang CJ, Tai KF, Lin SM, Hwang LH. Clin Cancer Res; 2005 Feb 15; 11(4):1639-49. PubMed ID: 15746069 [Abstract] [Full Text] [Related]
5. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Cancer Gene Ther; 2000 Jun 15; 7(6):826-38. PubMed ID: 10880012 [Abstract] [Full Text] [Related]
6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M. J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816 [Abstract] [Full Text] [Related]
7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H. Int J Oncol; 2006 Apr 15; 28(4):947-53. PubMed ID: 16525645 [Abstract] [Full Text] [Related]
8. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. Kinoshita Y, Kono T, Yasumoto R, Kishimoto T, Wang CY, Haas GP, Nishisaka N. J Immunother; 2001 Apr 15; 24(3):205-11. PubMed ID: 11394497 [Abstract] [Full Text] [Related]
10. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Sandler AD, Chihara H, Kobayashi G, Zhu X, Miller MA, Scott DL, Krieg AM. Cancer Res; 2003 Jan 15; 63(2):394-9. PubMed ID: 12543793 [Abstract] [Full Text] [Related]
11. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, Parmiani G, Trinchieri G, Colombo MP. Eur J Immunol; 1995 Jan 15; 25(1):137-46. PubMed ID: 7843224 [Abstract] [Full Text] [Related]
15. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. Cancer Res; 2002 Dec 15; 62(24):7254-63. PubMed ID: 12499267 [Abstract] [Full Text] [Related]
16. Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. Aruga A, Tanigawa K, Aruga E, Yu H, Chang AE. Cancer Gene Ther; 1999 Dec 15; 6(1):89-95. PubMed ID: 10078968 [Abstract] [Full Text] [Related]
17. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Belardelli F, Ferrantini M, Santini SM, Baccarini S, Proietti E, Colombo MP, Sprent J, Tough DF. Cancer Res; 1998 Dec 15; 58(24):5795-802. PubMed ID: 9865738 [Abstract] [Full Text] [Related]
18. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ. J Immunol; 1998 Jan 01; 160(1):334-44. PubMed ID: 9551989 [Abstract] [Full Text] [Related]
19. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Comes A, Di Carlo E, Musiani P, Rosso O, Meazza R, Chiodoni C, Colombo MP, Ferrini S. Eur J Immunol; 2002 Jul 01; 32(7):1914-23. PubMed ID: 12115611 [Abstract] [Full Text] [Related]
20. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO. Gene Ther; 2006 Jul 01; 13(13):1010-20. PubMed ID: 16525479 [Abstract] [Full Text] [Related] Page: [Next] [New Search]